NEULAND LABORATORIES LTD. - 524558 - Disclosure On Related Party Transactions For The Half Year Ended March 31, 2022 In Pdf Format.
We refer to our submission of Related Party Transactions pursuant to Regulation 23(9) of SEBI Listing Regulations, 2015 through XBRL on May 20, 2022. Further, please find enclosed herewith the disclosure on Related Party Transactions for the half year ended March 31, 2022 in pdf format. NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation to our intimation dated May 5, 2022, we would like to inform you that the audio recording and the transcript (attached) of the Earnings Call on Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022, held on May 10, 2022, have been uploaded on the website of the Company on May 10, 2022 and May 13, 2022 respectively. Please find below the weblinks to access the same: Web link to access audio recording is as under: https://www.neulandlabs.com/investors/investor-updates/investors-call-recordings/ Web link to access above transcript is as under: https://www.neulandlabs.com/investors/investor-updates/announcements/ This is for your information and records. NEULAND LABORATORIES LTD. - 524558 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Reg.24A-Annual Secretarial Compliance Report for the year ended March 31, 2022 NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Neuland Laboratories Limited has informed the Exchange about Newspaper Advertisements Earnings Call for Q4FY22 of Neuland Laboratories
Conference Call with Neuland Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript. NEULAND LABORATORIES LTD. - 524558 - Board recommends Final Dividend
Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2022, inter alia, have recommended payment of final dividend of Rs. 5.00/- (50%) per equity share on a face value of Rs.10 each, subject to the approval of members of the Company. Q4FY22 Quarterly Result Announced for Neuland Laboratories Ltd.
Pharmaceuticals firm Neuland Laboratories declares Q4FY22 result: Neuland FY22 income at Rs.953.2 crore EBITDA at Rs. 144.3 crore Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “The past financial year was marked by a flat revenue, owing principally to weak GDS offtake from our customers. Given our focus on building execution excellence, we remain confident about the long-term prospects of all our businesses despite facing certain technical issues with some late-stage CMS projects.” In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added “Our performance this year was a mixed bag. While our GDS business experienced a revenue decrease due to volume drop in certain key products, our input cost structures experienced an unusual increase. Given our focus on delivering complex projects in line with clients’ technical requirements, we retain our optimism that the overall business will grow in line with our stated expectations and reflect increased margins over the long term.” Result PDF NEULAND LABORATORIES LTD. - 524558 - Board Meeting Outcome for Outcome Of Board Meeting, Audited Results And Recommendation Of Final Dividend, For The Year Ended March 31, 2022
Outcome of Board Meeting, Audited results and recommendation of final dividend, for the year ended March 31, 2022 NEULAND LABORATORIES LTD. - 524558 - Results-Financial Results For The Year Ended March 31, 2022
Results-Financial Results for the year ended March 31, 2022